Clicky

Ovid Therapeutics Inc(1OT)

Description: Ovid Therapeutics Inc., a biopharmaceutical company, develops impactful medicines for patients and families with neurological disorders in the United States. The company is developing OV101, a drug candidate, which is in Phase 2A clinical trials for the treatment of fragile X syndrome; OV329, a GABA aminotransferase inhibitor for the treatment of seizures associated with tuberous sclerosis complex and infantile spasms; and OV350, a small molecule for treating epilepsies. It also develops OV882, a short hairpin RNA gene therapy for the treatment of angelman syndrome; and OV815 for the treatment of kinesin-family of proteins associated neurological disorder. The company has license and collaboration agreements with Healx, AstraZeneca AB, H. Lundbeck A/S, and Northwestern University, as well as Marinus Pharmaceuticals, Inc. The company was incorporated in 2014 and is headquartered in New York, New York.


Keywords: Medicine Biopharmaceutical Organ Systems Gene Therapy Neurological Disorders Epilepsy Seizure Syndromes Genodermatoses Fragile X Syndrome Neurological Disorder Lundbeck Infantile Spasms Angelman Syndrome Northwestern University Ov101 Tuberous Sclerosis

Home Page: www.ovidrx.com

1460 Broadway
New York, NY 10036
United States
Phone: 646 661 7661


Officers

Name Title
Dr. Jeremy Max Levin Ba Zoology, Dphil, Mb Bchir Pres, CEO & Chairman
Mr. Jeffrey A. Rona Principal Financial Officer, Principal Accounting Officer & Chief Bus. and Financial Officer
Mr. Thomas Michael Perone J.D., M.B.A. Gen. Counsel, Chief Compliance Officer & Corp. Sec.
Dr. Matthew J. During DSc, FACP, FRACP, M.D., Ph.D. Founder & Member of Scientific Advisory Board
Mr. Jason Tardio M.B.A. Chief Operating Officer
Ms. Lora Pike Sr. Director of Investor Relations & PR
Mr. Simon D. Kelner Sr. VP & Chief HR Officer
Dr. Dirk Haasner Sr. VP of Global Manufacturing & CMC QA
Ms. Suzanne K. Wakamoto SHRM-SCP, SPHR Sr. VP of Culture & Facilities
Dr. Claude Nicaise M.D. Head of R&D

Exchange: F

Country: DE : Germany

Currency: Euro (€)

Forward PE: 1.7486
Trailing PE: 0
Price-to-Book MRQ: 0.8805
Price-to-Sales TTM: 81.2617
IPO Date:
Fiscal Year End: December
Full Time Employees: 44
Back to stocks